Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset.
Common marmosets were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 1.25-2.5 mg/kg s.c., twice a week) for 5-10 consecutive months. The initial doses of MPTP produced a severe parkinsonian syndrome but motor activity was partially recovered at the end of treatment. Fifteen days or 6 months after the last MPTP dose, monkeys were sacrificed. In addition to a strong decrease of dopamine in the striatum, there were significant reductions in substance P and Met-enkephalin content in the substantia nigra, caudate nucleus and putamen. In the globus pallidus, the reduction in peptide levels did not reach statistical significance as compared to controls. Neurotensin levels were also decreased in the caudate nucleus. The chronic administration of MPTP for 5-10 months induces changes in substance P and Met-enkephalin systems which resemble the degeneration found in brains from parkinsonian patients.
Pérez-Otaño
I
I
Department of Pharmacology, University of Navarra Medical School, Pamplona, Spain.
Herrero
M T
MT
Luquin
M R
MR
Obeso
J A
JA
Del Río
J
J
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism*; D001522:Behavior, Animal / Q000187:drug effects; D002144:Callithrix; D004744:Enkephalin, Methionine / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012016:Reference Values; D013373:Substance P / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014018:Tissue Distribution
D013373:Substance P; D004744:Enkephalin, Methionine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine